STK11 and lung cancer: Similarly, the combination of CB‐839 with PD‐1 inhibition demonstrates better therapeutic outcomes in Kras‐mutant STK11‐/Lkb1‐deficient mouse models of lung cancer by restoring CD8+ T cell function and improving the TME [311].